| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
Corosolic acid has an ED50 of 0.4-5.0 μg/mL and is cytotoxic to Hep G2, A549, SNU-C4, HeLa, and K-562[1]. Corosolic acid (0-50 μg/mL) dose-dependently doubles corosolic acid (0-50 μM, 6-24 hours). Corosolic acid (0-50 μM, 6-24 hours) stimulates the sub-G1 cell population in CT-26 cells and multiplies its cell count [3]. In HCT116 and SW480 cells, crosolic acid (20 μM, 0-PKC activity [1]. 24 hours) suppresses HER2/HER3 heterodimerization and HER2 and HER3 phosphorylation [5].
|
|---|---|
| ln Vivo |
In the CT-26 allograft tumor model, corosolic acid (5, 25 mg/kg/day, peritumoral injection, 12 days) was demonstrated to impede tumor growth and have anti-angiogenic properties [3]. and 20 mg/kg, intraperitoneally, every two days) activates above the endoplasmic reticulum to suppress tumor growth in a mouse PC-3 xenograft model [4]. In high-fat fed rats, crosolic acid (10 mg/kg/d, dietary supplementation, 8 weeks) activates AMPK, inhibiting adipose tissue pathways and improving insulin resistance [6].
|
| Cell Assay |
Apoptosis analysis [3]
Cell Types: CT-26 Cell Tested Concentrations: 25 µM Incubation Duration: 12 and 24 h Experimental Results: Increased levels of cleaved caspase-3. There is an increase in cells in the sub-G1 population. Increased strand breaks in fluorescein-dUTP-labeled DNA. Western Blot Analysis [5] Cell Types: HCT116 and SW480 Cell Tested Concentrations: 20 μM Incubation Duration: 0-24 h Experimental Results: diminished NRG1-induced formation of HER2/HER3 heterodimers. Inhibits PI3K/Akt/PDE3B, but not the ERK1/2 signaling pathway. |
| Animal Protocol |
Animal/Disease Models: CT-26 allogeneic colon cancer mouse model [3]
Doses: 5, 25 mg/kg/day Route of Administration: peritumoral injection, 12 days Experimental Results: Tumor weight was diminished to 76.2% and 53.8% of the control group %. Blood and lymphatic vessels are less dense. Animal/Disease Models: High-fat fed mice [6] Doses: 10 mg/kg/day Route of Administration: Added to diet, 8 weeks Experimental Results: Inhibited hyperlipidemia, improved insulin sensitivity and glucose intolerance. Inhibits inflammation of adipose tissue. Inhibits macrophage infiltration into adipose tissue. |
| References | |
| Additional Infomation |
Corosolic acid is a triterpenoid. It has a role as a metabolite.
Corosolic acid has been reported in Salvia miltiorrhiza, Rosa laevigata, and other organisms with data available. See also: Lagerstroemia speciosa leaf (part of). |
| Molecular Formula |
C30H48O4
|
|---|---|
| Molecular Weight |
472.69972
|
| Exact Mass |
472.355
|
| CAS # |
4547-24-4
|
| PubChem CID |
6918774
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
573.3±50.0 °C at 760 mmHg
|
| Flash Point |
314.6±26.6 °C
|
| Vapour Pressure |
0.0±3.6 mmHg at 25°C
|
| Index of Refraction |
1.567
|
| LogP |
7.82
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
34
|
| Complexity |
908
|
| Defined Atom Stereocenter Count |
11
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~52.89 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.75 mg/mL (5.82 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.29 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1155 mL | 10.5775 mL | 21.1551 mL | |
| 5 mM | 0.4231 mL | 2.1155 mL | 4.2310 mL | |
| 10 mM | 0.2116 mL | 1.0578 mL | 2.1155 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
